JPH0747045B2
(ja)
|
1986-10-15 |
1995-05-24 |
株式会社大協精工 |
積層した注射器用滑栓
|
US5171840A
(en)
|
1988-01-22 |
1992-12-15 |
Tadamitsu Kishimoto |
Receptor protein for human B cell stimulatory factor-2
|
US5670373A
(en)
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
ATE356869T1
(de)
|
1990-01-12 |
2007-04-15 |
Amgen Fremont Inc |
Bildung von xenogenen antikörpern
|
US5016784A
(en)
|
1990-02-15 |
1991-05-21 |
Dexus Research Inc. |
Applicator for highly reactive materials
|
EP0628639B1
(en)
|
1991-04-25 |
1999-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin 6 receptor
|
JP2648897B2
(ja)
|
1991-07-01 |
1997-09-03 |
塩野義製薬株式会社 |
ピリミジン誘導体
|
WO1993000807A1
(en)
|
1991-07-03 |
1993-01-21 |
Cryolife, Inc. |
Method for stabilization of biomaterials
|
JP3100727B2
(ja)
|
1992-01-23 |
2000-10-23 |
株式会社大協精工 |
変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
|
AU670793B2
(en)
|
1992-04-30 |
1996-08-01 |
Alpha Therapeutic Corporation |
Improved solubilization and stabilization of factor VIII complex
|
WO1994009138A1
(en)
|
1992-10-20 |
1994-04-28 |
Cetus Oncology Corporation |
Interleukin-6 receptor antagonists
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
US5888511A
(en)
|
1993-02-26 |
1999-03-30 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS
|
US5888510A
(en)
|
1993-07-21 |
1999-03-30 |
Chugai Seiyaku Kabushiki Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
EP0791359A4
(en)
|
1994-10-21 |
2002-09-11 |
Chugai Pharmaceutical Co Ltd |
MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
|
DE69525971T3
(de)
|
1994-12-29 |
2013-01-10 |
Chugai Seiyaku K.K. |
Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin
|
EP0811384B1
(en)
|
1995-02-13 |
2006-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Muscle protein decomposition inhibitor containing il-6 receptor antibody
|
JP3172057B2
(ja)
|
1995-04-05 |
2001-06-04 |
株式会社大協精工 |
ラミネートゴム栓
|
EP0845997A1
(en)
|
1995-07-27 |
1998-06-10 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
JPH09154588A
(ja)
|
1995-10-07 |
1997-06-17 |
Toagosei Co Ltd |
Vegf結合性ポリペプチド
|
JP2000509018A
(ja)
|
1996-03-26 |
2000-07-18 |
イーライ・リリー・アンド・カンパニー |
肥満タンパク質製剤
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
DK0923941T3
(da)
|
1996-06-27 |
2006-09-18 |
Chugai Pharmaceutical Co Ltd |
Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US20020187150A1
(en)
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
CA2317411C
(en)
|
1998-01-30 |
2005-06-28 |
Scios Inc. |
Controlled release delivery of peptide or protein
|
JP4124573B2
(ja)
|
1998-03-17 |
2008-07-23 |
中外製薬株式会社 |
Il−6アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
|
JP3512349B2
(ja)
|
1999-01-29 |
2004-03-29 |
株式会社大協精工 |
柱状ゴム要素の成形型
|
US7001892B1
(en)
|
1999-06-11 |
2006-02-21 |
Purdue Research Foundation |
Pharmaceutical materials and methods for their preparation and use
|
EP1067182A3
(en)
|
1999-07-08 |
2001-11-21 |
Helix Research Institute |
Secretory protein or membrane protein
|
US7129338B1
(en)
|
1999-07-08 |
2006-10-31 |
Research Association For Biotechnology |
Secretory protein or membrane protein
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
US6670373B1
(en)
|
1999-10-07 |
2003-12-30 |
Eli Lilly And Company |
Compounds and method for inhibiting MRP1
|
EP1257572A2
(en)
|
2000-02-07 |
2002-11-20 |
Millennium Pharmaceuticals, Inc. |
Narc-1, subtilase-like homologs
|
US6659982B2
(en)
|
2000-05-08 |
2003-12-09 |
Sterling Medivations, Inc. |
Micro infusion drug delivery device
|
US6629949B1
(en)
|
2000-05-08 |
2003-10-07 |
Sterling Medivations, Inc. |
Micro infusion drug delivery device
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
JP4799803B2
(ja)
|
2000-09-08 |
2011-10-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
G−csfアナログ組成物および方法
|
ES2332402T5
(es)
|
2000-10-12 |
2018-05-14 |
Genentech, Inc. |
Formulaciones de proteína concentradas de viscosidad reducida
|
EP1334731B1
(en)
|
2000-10-25 |
2008-02-27 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
|
AU2000279625A1
(en)
|
2000-10-27 |
2002-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
JP2002209975A
(ja)
|
2001-01-19 |
2002-07-30 |
Daikyo Seiko Ltd |
医薬バイアル用ラミネートゴム栓
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
DE60235013D1
(de)
|
2001-07-25 |
2010-02-25 |
Facet Biotech Corp |
Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US20060078533A1
(en)
|
2004-10-12 |
2006-04-13 |
Omoigui Osemwota S |
Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
|
US20060078532A1
(en)
|
2004-10-12 |
2006-04-13 |
Omoigui Osemwota S |
Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
|
US20060275294A1
(en)
|
2002-08-22 |
2006-12-07 |
Omoigui Osemwota S |
Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
|
US20060078531A1
(en)
|
2004-10-12 |
2006-04-13 |
Osemwota Sota |
Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
PL2335725T3
(pl)
|
2003-04-04 |
2017-04-28 |
Genentech, Inc. |
Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
DE10355251A1
(de)
|
2003-11-26 |
2005-06-23 |
Merck Patent Gmbh |
Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
|
US8617550B2
(en)
|
2003-12-19 |
2013-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of vasculitis with IL-6 antagonist
|
JP2008505054A
(ja)
|
2004-02-11 |
2008-02-21 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
Il−6アンタゴニストで骨関節炎を治療する方法
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
RS20070027A
(en)
|
2004-07-26 |
2008-11-28 |
Biogen Idec Ma Inc., |
Anti-cd154 antibodies
|
US20110313024A1
(en)
|
2004-08-20 |
2011-12-22 |
Leonid Beigelman |
RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20070036788A1
(en)
|
2004-09-22 |
2007-02-15 |
Ahmed Sheriff |
Use of a compound for reducing the biological effectiveness of il-6
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
MX2007007277A
(es)
|
2004-12-16 |
2008-01-28 |
Genentech Inc |
Metodos para tratar trastornos autoinmunes.
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
RU2008118166A
(ru)
|
2005-11-22 |
2009-12-27 |
Вайет (Us) |
Составы, содержащие гибридные белки, включающие иммуноглобулин
|
US20080131374A1
(en)
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
CN101489565A
(zh)
|
2006-05-05 |
2009-07-22 |
Isis药物公司 |
调节pcsk9表达的化合物和方法
|
CA2651042A1
(en)
|
2006-05-05 |
2007-12-13 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of sglt2
|
ES2392478T3
(es)
|
2006-05-11 |
2012-12-11 |
Alnylam Pharmaceuticals Inc. |
Composiciones y métodos para inhibir la expresión del gen PCSK9
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
SI2364691T1
(sl)
|
2006-06-16 |
2013-08-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
WO2008057457A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
CN101636179B
(zh)
|
2006-11-07 |
2012-10-10 |
默沙东公司 |
Pcsk9拮抗剂
|
CA2667869A1
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
EP2106261A4
(en)
|
2006-11-07 |
2010-05-26 |
Merck Sharp & Dohme |
ANTAGONISTS OF PCSK9
|
EP2455471A3
(en)
|
2006-11-27 |
2012-09-12 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
CN101589143A
(zh)
|
2006-11-27 |
2009-11-25 |
Isis药物公司 |
用于治疗高胆固醇血症的方法
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
JP5100101B2
(ja)
|
2006-12-12 |
2012-12-19 |
キヤノン株式会社 |
画像形成装置
|
KR20100019440A
(ko)
|
2007-04-13 |
2010-02-18 |
노파르티스 아게 |
프로-단백질 전환효소 서브틸리신/켁신 유형 9 (pcsk9)를 조정하기 위한 분자 및 방법
|
EP2152752B1
(en)
|
2007-05-15 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Antibody directed to g protein coupled receptors (gpcr)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
WO2009042765A1
(en)
|
2007-09-25 |
2009-04-02 |
The Regents Of The University Of California |
Methods of modulating prokineticin 2 for treatment of stress response and anxiety-related disorders
|
AU2008304756B8
(en)
|
2007-09-26 |
2015-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-IL-6 receptor antibody
|
MX2010004454A
(es)
|
2007-10-26 |
2010-07-28 |
Schering Corp |
Anti-proproteina convertasa subtilisina/kexina tipo 9 y metodos para tratar trastornos de lipidos y colesterol.
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
PL2708558T3
(pl)
|
2008-04-11 |
2018-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
WO2010031720A2
(en)
|
2008-09-19 |
2010-03-25 |
F. Hoffmann-La Roche Ag |
Novel antibody formulation
|
MX2011003013A
(es)
|
2008-09-19 |
2011-04-11 |
Pfizer |
Formulacion liquida estable de anticuerpos.
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
WO2010068526A1
(en)
|
2008-12-12 |
2010-06-17 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
JO3672B1
(ar)
*
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
US20100216667A1
(en)
|
2008-12-17 |
2010-08-26 |
Meyer Brian K |
Method for determining compatibility of an active pharmaceutical ingredient with materials
|
KR20110128333A
(ko)
|
2009-03-06 |
2011-11-29 |
제넨테크, 인크. |
항체 제제
|
WO2010148013A2
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated dsrna targeting the pcsk9 gene
|
US20120114646A1
(en)
|
2009-06-18 |
2012-05-10 |
Wyeth Llc |
Lyophilized formulations for small modular immunopharmaceuticals
|
WO2011006000A1
(en)
|
2009-07-08 |
2011-01-13 |
Haiyan Liu |
Berberine derivatives useful for modulating lipid levels and their methods of synthesis
|
WO2011009697A1
(en)
|
2009-07-21 |
2011-01-27 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
TWI519685B
(zh)
|
2009-07-22 |
2016-02-01 |
國立大學法人信州大學 |
藍寶石單結晶之製造方法以及藍寶石單結晶之製造裝置
|
WO2011028938A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
WO2011037791A1
(en)
|
2009-09-25 |
2011-03-31 |
Merck Sharp & Dohme Corp. |
Antagonists of pcsk9
|
WO2011039578A1
(en)
|
2009-10-02 |
2011-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
|
WO2011053759A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax1 and ax189 pcsk9 antagonists and variants
|
WO2011053783A2
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax213 and ax132 pcsk9 antagonists and variants
|
MY165614A
(en)
|
2009-11-20 |
2018-04-18 |
Biocon Ltd |
Formulations of antibody
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
JO3274B1
(ar)
|
2009-12-24 |
2018-09-16 |
Regeneron Pharma |
أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
CN105218674A
(zh)
|
2010-03-11 |
2016-01-06 |
瑞纳神经科学公司 |
呈pH依赖性抗原结合的抗体
|
GB201005005D0
(en)
|
2010-03-25 |
2010-05-12 |
Angeletti P Ist Richerche Bio |
New vaccine
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
DE102010024698A1
(de)
|
2010-06-23 |
2011-12-29 |
Eads Deutschland Gmbh |
Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs
|
US10023657B2
(en)
|
2010-10-01 |
2018-07-17 |
Ludwig Institute For Cancer Research Ltd. |
Reversible protein multimers, methods for their production and use
|
EA034617B1
(ru)
|
2010-10-06 |
2020-02-27 |
Ридженерон Фармасьютикалз, Инк. |
Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r)
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
CA2817015A1
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
US8771696B2
(en)
|
2010-11-23 |
2014-07-08 |
Regeneron Pharmaceuticals, Inc. |
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
US9458240B2
(en)
|
2010-12-10 |
2016-10-04 |
Novartis Pharma Ag |
Anti-BAFFR antibody formulations
|
WO2012088313A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
BR112013018740A2
(pt)
|
2011-01-28 |
2019-01-08 |
Sanofi Sa |
anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
|
US20130315927A1
(en)
|
2011-02-11 |
2013-11-28 |
Novartis Ag |
Pcsk9 antagonists
|
US8440890B1
(en)
|
2011-03-09 |
2013-05-14 |
Pioneer Hi Bred International Inc |
Maize variety inbred PH1D0D
|
CA3021845C
(en)
|
2011-04-20 |
2022-03-29 |
Amgen Inc. |
Autoinjector apparatus
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
CA3051418C
(en)
|
2011-05-02 |
2021-05-18 |
Millennium Pharmaceuticals, Inc. |
Methods of treating inflammatory bowel disease
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
US20140004122A1
(en)
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
CA2746171C
(en)
|
2011-07-13 |
2018-11-06 |
William Jani |
Retrievable stimulation frac (rsf) plug
|
EP2731623A1
(en)
|
2011-07-14 |
2014-05-21 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
WO2013039969A1
(en)
|
2011-09-16 |
2013-03-21 |
Regeneron Pharmaceuticals, Inc. |
METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
NZ626955A
(en)
|
2012-03-08 |
2016-01-29 |
Hoffmann La Roche |
Abeta antibody formulation
|
EP2839037B1
(en)
|
2012-04-19 |
2018-12-26 |
Acetylon Pharmaceuticals, Inc. |
Biomarkers to identify patients that will respond to treatment and treating such patients
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
US20140093513A1
(en)
|
2012-05-25 |
2014-04-03 |
Catabasis Pharmaceuticals, Inc. |
Methods of lowering proprotein conversate subtilisin/kexin type 9 (pcsk9)
|
EP2882778B1
(en)
|
2012-08-13 |
2018-04-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
EP2703008A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
RU2538801C2
(ru)
|
2013-02-07 |
2015-01-10 |
Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" |
ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Arg-Pro-Gly-Pro В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
CN105705521A
(zh)
|
2013-06-07 |
2016-06-22 |
再生元制药公司 |
通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
|
JP6846931B2
(ja)
|
2013-10-11 |
2021-03-24 |
サノフィ・バイオテクノロジー |
高脂血症を処置するためのpcsk9阻害剤の使用
|
AU2014348765A1
(en)
|
2013-11-12 |
2016-06-09 |
Regeneron Pharmaceuticals, Inc. |
Dosing regimens for use with PCSK9 inhibitors
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US8945560B1
(en)
*
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
WO2015123423A2
(en)
|
2014-02-14 |
2015-08-20 |
Regeneron Pharmaceuticals, Inc |
Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
|
CN106794244A
(zh)
|
2014-03-17 |
2017-05-31 |
赛诺菲生物技术公司 |
用于降低心血管风险的方法
|
WO2015140079A1
(en)
|
2014-03-17 |
2015-09-24 |
Sanofi |
Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
|
KR20170029613A
(ko)
|
2014-07-16 |
2017-03-15 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
US20160137746A1
(en)
|
2014-07-16 |
2016-05-19 |
Sanofi Biotechnology |
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
CA2995645A1
(en)
|
2015-08-18 |
2017-02-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
|
US10933134B2
(en)
|
2017-03-16 |
2021-03-02 |
Memorial Sloan Kettering Cancer Center |
Combination therapies for treatment of cancer
|
TW202310872A
(zh)
|
2017-06-09 |
2023-03-16 |
法商賽諾菲生物技術公司 |
藉由投予pcsk9抑制劑治療糖尿病患者高血脂症之方法
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
KR20200129127A
(ko)
|
2018-03-06 |
2020-11-17 |
사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 |
심혈관 위험을 감소시키기 위한 pcsk9 억제제의 용도
|